ArticleBrain and behavior2026
Oligodendrocyte and Astrocyte Dynamics During Short-Term Cuprizone Treatment.
Article in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeGlial cells, including oligodendrocytes (OLs), astrocytes, and microglia, are brain cells that support and dynamically interact with neurons and each other. These intercellular dynamics undergo changes during stress and disease states. Studies have reported cross talk between glial cells, such as astrocytes, microglia, and OL precursor cells (OPCs), and recruitment to central nervous system (CNS) lesions. However, the dynamics of this interaction are still unclear, especially during the early time point of exposure to cuprizone (CPZ).
methodsIn this study, we exposed mice to CPZ treatment for a short duration (3 days and 1 week); we used immunohistochemistry to quantify Aspartoacylase (ASPA)-positive OLs, complement component 3d (C3d)-positive astrocytes (A1 subtype), and epithelial membrane protein 1 (Emp1)-positive astrocytes (A2 subtype). Gene expression levels of myelinating OLs were quantified using reverse transcription polymerase chain reaction (RT-PCR), and protein expression of C3d and Emp1 was quantified using Western blot. FINDING: After 3 days of CPZ treatment, there was a significant increase in the expression of the astrocyte A2 marker (Emp1) and a significant decrease in mature OLs marked by ASPA. No significance was observed for C3d at 3 days and 1 week. Additionally, the Myelin Basic Protein (MBP) gene, which also shows the expression level of myelin, was significantly downregulated at 3 days. Previous work indicates that CPZ causes blood-brain barrier (BBB) permeability as early as 3 days, with subsequent microglial and astrocyte activation before demyelination.
conclusionThis study suggests an interaction between OLs death and astrocyte subtypes activation during CPZ treatment at early time points (3 days and 1 week) before overt demyelination. Understanding this cross talk and the changes in their activation and interaction is important for developing methods to prevent or reverse demyelination.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.